A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Isolation, Characterization, and Proteomic Analysis of Plasma-Derived Extracellular Vesicles for Cardiovascular Biomarker Discovery

1.4K views

⸱

DOI:

10.3791/67083

⸱

January 31st, 2025

 ,  ,  ,  ,  ,  ,  ,  , 
1Department of Cardiology, Angiology and Pulmonology, University Hospital Heidelberg, 2Heart and Vascular Center, Semmelweis University, 3Core Facility for Mass Spectrometry and Proteomics, Centre for Molecular Biology at Heidelberg University (ZMBH), 4German Centre for Cardiovascular Research (DZHK), Partner site Heidelberg/Mannheim

* These authors contributed equally

In This Article

Summary

This article describes a methodology for the isolation, characterization, and quantification of human plasma-derived extracellular vesicles (EV) and presents a workflow for label-free analysis of the EV proteome using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Abstract

Extracellular vesicles (EV) are cell-derived, lipid bilayer-enclosed, non-replicable nanoparticles. EV currently gain attention in cardiovascular research due to their role in regulating intercellular communication, potentially serving as valuable biomarkers for cardiovascular disease. However, the EV proteome and its potential as a biomarker in cardiovascular diagnostics remain poorly understood. This protocol presents a standardized method for the isolation and quantification of plasma-derived EV and the analysis of their protein cargo using plasma samples from patients presenting to the Chest Pain Unit of a large university hospital. Following routine phlebotomy, EV are isolated from plasma by differential ultracentrifugation. The enrichment of specific EV marker proteins in EV isolates is visualized by immunoblotting, and average size distribution and plasma EV concentrations are quantified by nanoparticle tracking analysis. Finally, ultra-performance liquid chromatography-tandem mass spectrometry is employed for label-free analysis of the EV proteome. This protocol thus provides a comprehensive approach to study and use plasma-derived EV as potential carriers of critical biological information as well as to explore their potential as novel biomarkers.

Introduction

Extracellular vesicles (EV), by nomenclature not uniformly defined, are nanoparticles surrounded by a lipid bilayer and released by various cell types, lacking the ability to replicate1. This diverse group includes exosomes, a subpopulation of EV of endosomal origin, typically ranging from approximately 40 nm to 160 nm in diameter2. Detectable in numerous body fluids3, EVs facilitate intercellular communication by transferring various active biomolecules such as proteins, mRNA, microRNA, and lipids. Thus, EV provide information about their cell of origin through cell-specific surface markers and biomolecules, with their properties strongly influenced by the condition of the parent cell and its environment4. These characteristics have led to a growing interest in the potential role of EV as biomarkers, particularly in the context of cardiovascular diseases.

Numerous in vitro and in vivo studies have demonstrated that myocardial hypoxic stress leads to an increased release of EV5,6,7. Contemporary research on EV cargo has largely focused on EV-bound microRNA, which has the potential to serve as a biomarker in the diagnosis of various cardiovascular diseases8,9,10. In contrast, evidence on the circulating EV proteome remains relatively scarce, with even fewer studies investigating plasma EV in cardiovascular patients. In two comprehensive studies on plasma-derived EV from patients suffering myocardial infarction, the authors identified a specific ischemia-induced EV proteome profile with potential diagnostic relevance6,11.

The methodological processing of EV has historically proven challenging, and currently, there is no definitive recommendation for the optimal approach to EV isolation, characterization, and quantification. Commonly used methods for EV isolation include differential ultracentrifugation, density-gradient centrifugation, and filtration methods such as size-exclusion chromatography1. According to current consensus guidelines, the characterization of EV isolates should include evidence of at least three typical EV surface protein markers, such as tetraspanins or annexins, combined with an imaging modality1. To examine EV cargo at the protein level, antibody-based methods such as Western blot or ELISA are most frequently utilized.

Given the methodological challenges associated with the isolation and processing of circulating EV, this protocol presents a comprehensive pathway from patient recruitment and sample collection to subsequent EV isolation, characterization, and quantification of plasma EV isolates. Additionally, this study showcases a workflow for the immediate isolation of plasma-derived EV from patients presenting to the emergency department (Chest Pain Unit) at a tertiary care center in southwestern Germany, followed by the label-free analysis of disease-specific plasma EV proteome using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The aim is to facilitate a high-throughput analysis to identify differentially enriched EV-bound proteins across a large cohort of patients with diverse ischemic, congenital, or (auto-)immune cardiovascular diseases at the initial diagnosis and throughout disease progression and/or resolution. This proteomic screening approach seeks to identify patterns of EV-specific protein enrichment associated with distinct disease pathways, with the ultimate goal of uncovering novel EV-bound protein biomarkers to enhance current diagnostics and therapeutic monitoring in cardiovascular disease.

Access restricted. Please log in or start a trial to view this content.

Protocol

For this protocol, an exemplary patient cohort was recruited comprising three healthy control patients with no signs of apparent or underlying cardiovascular disease and two patients with non-ST elevated myocardial infarction (NSTEMI). Prior approval was granted by the Institutional Review Board of the Medical Faculty of the University of Heidelberg (IRB approval #S-351/2015), and written consent was obtained from all patients prior to recruitment. Patients were recruited from the Chest Pain Unit of the Department of Cardiology at University Hospital Heidelberg based on initial clinical presentation, medical history, and the results of diagnostic testing.

Inclusion criteria for healthy control patients included atypical or nonspecific clinical presentation, cardiac biomarker levels within normal limits, no history of cardiovascular disease, and normal findings on any further diagnostic testing. Exclusion criteria included a history of malignancy or cytostatic therapy within the last five years, hemodialysis, familial hyperlipidemia syndromes, and any history of cardiovascular disease. NSTEMI was diagnosed following current guidelines12, with hemodynamically relevant coronary stenosis confirmed by coronary angiography. For each patient, up to 36 mL of blood was collected from the antecubital vein into citrate-supplemented collection tubes via standard phlebotomy13, and blood samples were immediately transported at 4 °C for further processing. Details of the reagents and equipment used in this study are listed in the Table of Materials.

1. EV isolation using differential centrifugation

NOTE: A differential centrifugation protocol was employed to isolate EV from human plasma samples. Two ultracentrifugation (UC) cycles with increasing centrifugal force were conducted to maximize purity of the resulting EV pellet.

  1. Plasma isolation
    1. Start processing whole blood samples, cooled at 4 °C, within 120 min of collection to ensure plasma EV integrity. Use citrate-supplemented blood collection tubes (0.106 mol/L citrate) to prevent coagulation.
    2. Dilute 9 mL of citrated whole blood 1:1 in ice-cold phosphate-buffered saline (PBS) to reduce viscosity. Add 5 mL of density gradient medium (1.077 g/mL) for separation during centrifugation.
    3. Centrifuge at 600 × g for 25-30 min at 4 °C. Carefully pipette off the plasma fraction from the top of each column into specialized centrifugation tubes. Proceed to the next steps or freeze at -80 °C.
  2. Removal of cell debris and apoptotic bodies
    1. Centrifuge the plasma at 20,000 × g for 15 min at 4 °C using an ultracentrifuge with a fixed-angle rotor, without braking. A visible pellet of cell debris and apoptotic bodies should form at the bottom of the tube.
  3. EV isolation
    1. Transfer the supernatant to a new tube. Ultracentrifuge at 100,000 × g for 2 h at 4 °C, without braking, to isolate EV, which will form a visible pellet on the tube wall.
    2. Carefully pipette off the supernatant using an electronic pipette, leaving about 1 mL of EV-depleted plasma. Switch to a 1000 µL pipette for the remaining plasma, pipetting slowly to avoid disturbing the EV pellet. Tilt the tube gradually while pipetting to ensure no plasma remains in the tube.
  4. Preparation for downstream analysis
    1. Resuspend the isolated EV pellet according to downstream analysis requirements: for nanoparticle tracking, resuspend the EV pellet from 9 mL of whole blood in 200 µL of PBS; for LC-MS/MS, resuspend EV isolated from 36 mL of whole blood in 50 µL of 1x RIPA buffer with 1% protease/phosphatase inhibitor
    2. Transfer the resuspended EV pellet to a 1.5-2 mL tube. Store at -80 °C until further analysis or proceed as needed.

2. Nanoparticle tracking analysis

NOTE: The quantification of average EV size distribution in human plasma samples was conducted using Nanoparticle Tracking Analysis (NTA), a laser-based detection method that analyzes the Brownian motion of nanoparticles.

  1. Working dilutions for NTA
    1. Dilute the EV stock solution (EV pellet resuspended in 200 μL PBS) with ice-cold PBS at ratios of 1:10, 1:50, 1:100, and 1:200. Create various working dilutions to determine the most suitable dilution for achieving a final count of 10-100 nanoparticles per frame during nanoparticle tracking.
  2. Running NTA
    1. Switch on the NTA instrument and launch the applicable software on the connected computer. Place the chamber inside the laser casket and click on Start Camera to activate it.
    2. Draw 1 mL of PBS into a syringe. Plug the syringe into the front tube and thoroughly flush the tubing system, ensuring no air remains in the chamber. Monitor the camera to detect any air bubbles or contaminating particles.
    3. Draw up the prepared EV working dilution in a 1 mL syringe and inject it into the chamber.
    4. Adjust the Screen Gain to match the monitor's brightness in the Capture and Process tabs. Modify the Camera Level to differentiate nanoparticles clearly on the screen.
    5. Set a suitable Detection Threshold in the Process tab to adjust the sensitivity for differentiating particles from background noise. Keep this value constant for all measurements within the same experiment.
    6. Focus the camera using the wheel on each side of the instrument until the nanoparticles appear sharp on the screen.
    7. Set a constant temperature (ideally 22 °C) for all measurements in the Hardware settings, as Brownian motion is temperature-dependent.
    8. Click on the Run button to start measurement. Enter the sample ID and the solvent in the pop-up window.
    9. Record a minimum of three 30 s videos for each sample run. Advance the sample between measurements to capture a representative sample of the nanoparticle solution. If a syringe pump is available, set it at a constant speed and record continuously.
    10. After recording, the software automatically calculates the concentration and size distribution of nanoparticles. Click on Change to enter the dilution factor used for the sample, and then save the results by clicking on Export.
  3. Data analysis
    1. Analyze the results using the output files in a statistical software program.

Label-free analysis of EV proteome using liquid chromatography-tandem mass spectrometry (LC-MS/MS)

NOTE: Label-free EV proteome analysis was conducted using initial protein separation through gel electrophoresis of EV proteins following membrane lysis. After in-gel protein digestion with trypsin, peptides were analyzed using LC-MS/MS, with individual spectra matched against a human proteome database. Notably, if an untargeted analysis of EV lysates is desired, shotgun proteomics without prior selection of a specific molecular weight range is recommended, making steps 3.1.1-3.1.7 of this protocol unnecessary.

  1. In-gel trypsin digestion
    1. Prepare a solution of EV resuspended in 1x RIPA buffer by adding Laemmli loading buffer according to the manufacturer's instructions (see Table of Materials). Boil samples at 95 °C for 5 min.
    2. Load the EV samples, supplemented with loading buffer, along with a protein ladder onto 4%-12% Bis-Tris gels for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)14. Stain the gel with Coomassie Blue for 1-4 h to visualize protein bands. De-stain the gel with water by incubating overnight.
    3. Excise Coomassie-stained bands from gel regions containing proteins of interest using a scalpel blade.
    4. Wash the gel pieces with 60 µL of 1:1 (v/v) 50 mM triethylammonium bicarbonate buffer (TEAB) and acetonitrile (ACN), pH 8.5, for 10 min. Shrink the gel pieces three times for 10 min each in 60 µL of ACN. Wash again with 60 µL 50 mM TEAB, pH 8.5.
    5. Reduce the proteins with 10 mM dithiothreitol (DTT) in 100 mM of TEAB at 57 °C for 30 min and dehydrate the gel pieces.
    6. Alkylate the proteins with 10 mM iodoacetamide (IAA) in 100 mM of TEAB at 25 °C for 20 min in the dark.
    7. Wash the gel pieces with 60 µL of 100 mM TEAB and shrink them twice for 10 min each in 60 µL of ACN.
    8. Add 50 mM of TEAB trypsin solution, concentrated accordingly, to the dry gel pieces. Incubate for 4 h at 37 °C. Quench the reaction by adding 20 µL of 0.1% trifluoroacetic acid (TFA).
    9. Extract the resulting peptides by incubating with 30 µL of 1:1 (v/v) 0.1% TFA and ACN for 30 min. Dehydrate the gels with 20 µL of ACN for 20 min, then wash again with 30 µL of 100 mM TEAB for 20 min.
    10. Shrink the gel twice with 20 µL of ACN for 20 min each.
    11. Concentrate the supernatant collected from each extraction step in a vacuum centrifuge and dissolve the sample in 15 µL of 0.1% TFA.
  2. LC-MS/MS analysis
    1. Perform nanoflow LC-MS/MS analysis using a high-resolution liquid chromatography mass spectrometer coupled to an electrostatic ion trap analyzer.
    2. Use 0.1% formic acid (FA)/1% ACN as solvent A and 0.1% FA/89.9% ACN as solvent B.
    3. Separate the peptides in a 25-min linear gradient: start from 3% solvent B, increase B to 23% over 21 min, then to 38% over 4 min, and proceed with a washout at 95% B.
    4. Operate the mass spectrometer in data-dependent acquisition mode, automatically alternating between MS and MS2. Acquire MS spectra (m/z 400-1600) with a resolution of 60,000 at m/z 400, generating MS2 spectra for up to 15 precursors using a normalized collision energy of 27 and an isolation width of 1.4 m/z.
  3. Protein database search
    1. Search the MS/MS spectra against the Swiss-Prot Homo sapiens (UP000005640, June 2020) protein database and a customized contaminant database (part of MaxQuant, MPI Martinsried15,16) using Proteome Discoverer 2.5 with Sequest HT.
    2. Configure the program settings as follows: set the fragment ion mass tolerance to 0.02 Da and the parent ion mass tolerance to 5 ppm. Specify trypsin as the enzyme used for digestion, and set carbamidomethyl as a fixed modification for cysteine, with oxidation (methionine) and deamidation (asparagine, glutamine) as variable modifications. Include acetylation, methionine loss, and their combination as variable modifications of the protein terminus.
    3. Quantify peptides using the precursor ion quantifier mode, employing the Top N Average (n = 3) method for protein abundance calculation17.

Access restricted. Please log in or start a trial to view this content.

Results

EV were isolated from plasma samples (n = 3) of patients without overt cardiovascular disease, as well as from patients with non-ST elevation myocardial infarction (NSTEMI; n = 2), using the established differential ultracentrifugation protocol. Adequate separation of plasma EV was confirmed by immunoblotting of EV-enriched proteins TSG-101, annexin 5 (Anx5), and CD9 in EV isolates compared to EV-depleted plasma from the same patients (Figure 1A). Transferrin, serving as a negative control, ...

Access restricted. Please log in or start a trial to view this content.

Discussion

This protocol provides a real-world, step-by-step, ready-to-use methodology for the separation and characterization of plasma EV, as well as an introduction to an unlabeled proteome analysis suitable for integration into routine clinical practice. A detailed description and strict adherence to a unified methodology for EV isolation from plasma samples are important to ensure reproducibility of obtained results. Current literature indicates that pre-analytical conditions can significantly impact subsequent measurements an...

Access restricted. Please log in or start a trial to view this content.

Disclosures

EG received honoraria for lecturers from Roche Diagnostics, BRAHMS Thermo Scientific, Bayer Vital GmbH, AstraZeneca, Lilly Deutschland, Boehringer Ingelheim; he received institutional research grants from Roche Diagnostics and Daiichi Sankyo, and serves as a consultant for Roche Diagnostics, BRAHMS Thermo Scientific, Astra Zeneca, Novartis and Boehringer Ingelheim, outside the submitted work. JBK received project-related funding from the German Centre for Cardiovascular Research (DZHK) and Roche Diagnostics. The remaining authors declare no conflict of interest related to the submitted work.

Acknowledgements

The authors thank Heidi Deigentasch, Amelie Werner, and Elisabeth Mertz for their organizational support during this project.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
4x Laemmli sample buffferBio-rad1610747
10x RIPA-BufferAbcamab156034
26.3 mL Polycarbonate Bottle with Cap Assembly for UltracentrifugationBeckman Coulter355654
5810R Benchtop centrifugeEppendorf5811000015
Acetonitrile (ACN)Biosolve0001204101BS
Dithiothreitol (DTT)Sigma-Aldrich43816-10ML
Dulbecco's Phosphate buffered saline (PBS)Sigma-AldrichD8537
Formic Acid 99% ULC/MS 100Biosolve0006914143BS
Histopaque - 1077Sigma-Aldrich10771
Iodoacetamide (IAA)Sigma-AldrichI6125-5G
Mass Spectrometer Orbitrap Q Exactive HFThermo Fisher ScientificIQLAAEGAAPFALGMBDK
MOPS SDS running bufferThermo FisherB0001
NanoSight NS300Malvern Panalytical NS300
Nanosight NTA 3.2 SoftwareMalvern Panalytical 
NuPAGE 4 bis 12 %, Bis-Tris protein gelsInvitrogenNP0323
Optima XPN-80 floor-standing ultracentrifugeBeckman Coulter521-4180
PageRuler Plus Prestained Protein LadderThermo Fisher Scientific26619
Protease/Phosphatase Inhibitor Cocktail (100X)Cell Signaling Technology5872S
Protein markerThermo Fisher26616
Proteome Discoverer 2.5Thermo Fisher
Q Exactive Plus Hybrid Quadrupole-Orbitrap Mass SpectrometerThermo Fisher ScientificIQLAAEGAAPFALGMBDK
Quick stain coomasssieServa35081.01
ReproSil-Pur 120 C18-AQ, 1.9 µm 1 gDr. Maischr119.aq.0001
SDS-PAGE commercial gelThermo FisherNW00100BOX
S-Monovette Citrat 9NC 0.106 mol/l 3,2%Sarstedt02.1067.001
Speed vac concentratorSavant
Swiss-Prot (Uniprot) Homo sapiens (UP000005640, June 2020) protein databaseUniProthttps://www.uniprot.org/proteomes/UP000005640
Triethylammonium bicarbonate buffer (TEAB)Sigma-AldrichT7408
Trifluoroacetic acid (TFA) for HPLC >99%, 100 mLSigma-Aldrich302031-100ML
Trypsin MS-GradeThermo Fisher90058
Type 50.2 Ti Fixed-Angle RotorBeckman Coulter337901
UHPLC Dionex Ultimate 3000Thermo Fisher ScientificULTIM3000RSLCNANO
WaterBiosolve0023214102BS

References

  1. Thery, C., et al. Minimal information for studies of extracellular vesicles 2018 (misev2018): A position statement of the international society for extracellular vesicles and update of the misev2014 guidelines. J Extracell Vesicles. 7 (1), 1535750(2018).
  2. Kalluri, R., Lebleu, V. S. The biology, function, and biomedical applications of exosomes. Science. 367, 6478(2020).
  3. Shah, R., Patel, T., Freedman, J. E. Circulating extracellular vesicles in human disease. N Engl J Med. 379 (22), 2180-2181 (2018).
  4. Zara, M., Amadio, P., Campodonico, J., Sandrini, L., Barbieri, S. S. Exosomes in cardiovascular diseases. Diagnostics (Basel). 10 (11), 943(2020).
  5. Ontoria-Oviedo, I., et al. Extracellular vesicles secreted by hypoxic ac10 cardiomyocytes modulate fibroblast cell motility. Front Cardiovasc Med. 5, 152(2018).
  6. Zara, M., et al. Plasma exosome profile in st-elevation myocardial infarction patients with and without out-of-hospital cardiac arrest. Int J Mol Sci. 22 (15), (2021).
  7. Anselmo, A., et al. Myocardial hypoxic stress mediates functional cardiac extracellular vesicle release. Eur Heart J. 42 (28), 2780-2792 (2021).
  8. Navickas, R., et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: A systematic review. Cardiovasc Res. 111 (4), 322-337 (2016).
  9. Creemers, E. E., Tijsen, A. J., Pinto, Y. M. Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease. Circ Res. 110 (3), 483-495 (2012).
  10. Deddens, J. C., et al. Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J Cardiovasc Transl Res. 6 (6), 884-898 (2013).
  11. Gidlof, O., et al. Proteomic profiling of extracellular vesicles reveals additional diagnostic biomarkers for myocardial infarction compared to plasma alone. Sci Rep. 9 (1), 8991(2019).
  12. Byrne, R. A., et al. ESC guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 10, (2023).
  13. Garcia-Castrillo, L., et al. Recommendations for blood sampling in emergency departments from the European Society for Emergency Medicine (EUSEM), European Society for Emergency Nursing (EUSEN), and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) working group for the pre-analytical phase. Clin Chem Lab Med. 62 (8), 1538-1547 (2024).
  14. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227 (5259), 680-685 (1970).
  15. Cox, J., et al. Andromeda: A peptide search engine integrated into the maxquant environment. J Proteome Res. 10 (4), 1794-1805 (2011).
  16. Cox, J., Mann, M. Maxquant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 26 (12), 1367-1372 (2008).
  17. Blein-Nicolas, M., Zivy, M. Thousand and one ways to quantify and compare protein abundances in label-free bottom-up proteomics. Biochim Biophys Acta. 1864 (8), 883-895 (2016).
  18. Lacroix, R., et al. Standardization of pre-analytical variables in plasma microparticle determination: Results of the international society on thrombosis and haemostasis SSC collaborative workshop. J Thromb Haemost. 11 (6), 1190-1193 (2013).
  19. Nieuwland, R., Siljander, P. R. A beginner's guide to study extracellular vesicles in human blood plasma and serum. J Extracell Vesicles. 13 (1), e12400(2024).
  20. Lacroix, R., et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: Towards standardization of protocol. J Thromb Haemost. 10 (3), 437-446 (2012).
  21. Coumans, F. aW., et al. Methodological guidelines to study extracellular vesicles. Circ Res. 120 (10), 1632-1648 (2017).
  22. Clayton, A., et al. Considerations towards a roadmap for collection, handling and storage of blood extracellular vesicles. J Extracell Vesicles. 8 (1), 1647027(2019).
  23. Lucien, F., et al. Miblood-EV: Minimal information to enhance the quality and reproducibility of blood extracellular vesicle research. J Extracell Vesicles. 12 (12), e12385(2023).
  24. Zhang, X., Takeuchi, T., Takeda, A., Mochizuki, H., Nagai, Y. Comparison of serum and plasma as a source of blood extracellular vesicles: Increased levels of platelet-derived particles in serum extracellular vesicle fractions alter content profiles from plasma extracellular vesicle fractions. PLoS One. 17 (6), e0270634(2022).
  25. Gelibter, S., et al. The impact of storage on extracellular vesicles: A systematic study. J Extracell Vesicles. 11 (2), e12162(2022).
  26. Sluijter, J. P. G., et al. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position paper from the working group on cellular biology of the heart of the European Society of Cardiology. Cardiovasc Res. 114 (1), 19-34 (2018).
  27. Davidson, S. M., et al. Methods for the identification and characterization of extracellular vesicles in cardiovascular studies: From exosomes to microvesicles. Cardiovasc Res. 119 (1), 45-63 (2023).
  28. Karimi, N., et al. Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins. Cell Mol Life Sci. 75 (15), 2873-2886 (2018).
  29. Brennan, K., et al. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep. 10 (1), 1039(2020).
  30. Palviainen, M., et al. Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo-implications for biomarker discovery. PLoS One. 15 (8), e0236439(2020).
  31. Lotvall, J., et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the international society for extracellular vesicles. J Extracell Vesicles. 3, 26913(2014).
  32. Gemoll, T., et al. Protein profiling of serum extracellular vesicles reveals qualitative and quantitative differences after differential ultracentrifugation and ExoQuick TM isolation. J Clin Med. 9 (5), 1429(2020).
  33. Kreimer, S., et al. Mass-spectrometry-based molecular characterization of extracellular vesicles: Lipidomics and proteomics. J Proteome Res. 14 (6), 2367-2384 (2015).
  34. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V., Mann, M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 1 (6), 2856-2860 (2006).
  35. Bateman, N. W., et al. Maximizing peptide identification events in proteomic workflows using data-dependent acquisition (dda). Mol Cell Proteomics. 13 (1), 329-338 (2014).
  36. Pino, L. K., Just, S. C., Maccoss, M. J., Searle, B. C. Acquiring and analyzing data independent acquisition proteomics experiments without spectrum libraries. Mol Cell Proteomics. 19 (7), 1088-1103 (2020).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Plasma Extracellular VesiclesCardiovascular BiomarkersEV IsolationNanoparticle TrackingDifferential UltracentrifugationImmunoblottingProtein BiomarkersClinical ProteomicsPlasma Biomarker Discovery
Isolation, Characterization, and Proteomic Analysis of Plasma-Derived Extracellular Vesicles for Cardiovascular Biomarker Discovery
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.